Radius Health (RDUS) Raised to “Hold” at Zacks Investment Research
Zacks Investment Research upgraded shares of Radius Health (NASDAQ:RDUS) from a sell rating to a hold rating in a research note issued to investors on Monday morning.
According to Zacks, “Radius received a major boost with the approval of Tymlos for the treatment of postmenopausal women with high risk osteoporosis for fracture. Although the osteoporosis market has a great potential as approximately 1.4 million postmenopausal women in the United States experience an osteoporotic fracture each year, Tymlos is expected to face significant competition from Eli Lilly &Co's Forteo and Amgen’s Prolia. Further, the company suffered a setback when the CHMP issued a second Day-180 List of Outstanding Issues to its MAA for Eladynos in Europe. The CHMP will issue a third Day-180 List of Outstanding Issues in its regulatory review of abaloparatide-SC. While Radius' efforts in developing its pipeline are encouraging, we note that most of its candidates are in their early or mid stages of development. The company’ shares have underperformed the industry in the last twelve months.”
A number of other equities research analysts have also recently issued reports on the company. Cantor Fitzgerald reaffirmed a buy rating and set a $58.00 target price on shares of Radius Health in a research report on Friday, November 3rd. Jefferies Group decreased their target price on Radius Health from $38.00 to $31.00 and set a hold rating for the company in a research report on Friday, November 3rd. BidaskClub cut Radius Health from a sell rating to a strong sell rating in a research report on Thursday, December 7th. Citigroup began coverage on Radius Health in a research report on Wednesday, December 6th. They issued a neutral rating and a $30.00 price objective for the company. Finally, ValuEngine raised Radius Health from a strong sell rating to a sell rating in a research report on Friday, December 1st. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of Hold and an average price target of $48.00.
Radius Health (NASDAQ:RDUS) last announced its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.03). The business had revenue of $13.50 million during the quarter, compared to analysts’ expectations of $6.90 million. During the same period in the prior year, the firm earned ($1.07) earnings per share. analysts expect that Radius Health will post -5.57 EPS for the current year.
In other Radius Health news, VP Brent Hatzis-Schoch acquired 1,778 shares of Radius Health stock in a transaction dated Friday, November 10th. The stock was bought at an average cost of $28.09 per share, with a total value of $49,944.02. Following the completion of the transaction, the vice president now owns 2,278 shares of the company’s stock, valued at $63,989.02. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Growth N. V. Biotech acquired 50,000 shares of Radius Health stock in a transaction dated Friday, November 3rd. The stock was acquired at an average cost of $29.15 per share, with a total value of $1,457,500.00. Following the completion of the transaction, the insider now directly owns 5,648,799 shares of the company’s stock, valued at approximately $164,662,490.85. The disclosure for this purchase can be found here. Insiders bought 158,578 shares of company stock valued at $4,659,916 over the last three months. 15.00% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Ameritas Investment Partners Inc. boosted its position in shares of Radius Health by 19.9% in the second quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock valued at $148,000 after acquiring an additional 541 shares during the period. Sei Investments Co. raised its stake in shares of Radius Health by 27.7% in the second quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 690 shares in the last quarter. Cornerstone Capital Management Holdings LLC. raised its stake in shares of Radius Health by 4.1% in the second quarter. Cornerstone Capital Management Holdings LLC. now owns 17,605 shares of the biopharmaceutical company’s stock valued at $795,000 after purchasing an additional 690 shares in the last quarter. Principal Financial Group Inc. raised its stake in shares of Radius Health by 14.1% in the second quarter. Principal Financial Group Inc. now owns 6,809 shares of the biopharmaceutical company’s stock valued at $308,000 after purchasing an additional 839 shares in the last quarter. Finally, California Public Employees Retirement System raised its stake in shares of Radius Health by 2.3% in the second quarter. California Public Employees Retirement System now owns 71,600 shares of the biopharmaceutical company’s stock valued at $3,238,000 after purchasing an additional 1,600 shares in the last quarter.
WARNING: “Radius Health (RDUS) Raised to “Hold” at Zacks Investment Research” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2018/01/09/radius-health-rdus-raised-to-hold-at-zacks-investment-research.html.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related stocks with our FREE daily email newsletter.